Printer Friendly
The Free Library
23,396,934 articles and books


Axonyx Receives Notice Related to Nasdaq Minimum Bid Price Rule.

NEW YORK -- Axonyx Inc. (NASDAQ: AXYX), a U.S.-based biopharmaceutical company, today announced that it received notice on December 21, 2005 from The Nasdaq Stock Market, Inc. that the minimum bid price of the Company's common stock had fallen below $1.00 for 30 consecutive business days and that the Company was therefore not in compliance with Nasdaq Marketplace Rule 4310(c)(4).

In accordance with the Nasdaq Marketplace Rules, the Company has until June 19, 2006, (180 calendar days from December 21, 2005) to regain compliance.

The Company can regain compliance with the minimum bid price rule if the bid price of its common stock closes at $1.00 or higher for a minimum of 10 consecutive business days during the initial 180-day period, although Nasdaq may, in its discretion, require the Company to maintain a bid price of at least $1.00 per share for a period in excess of ten consecutive business days (but generally no more than 20 consecutive business days) before determining that the Company has demonstrated the ability to maintain long-term compliance. If compliance is not achieved by June 19, 2006, the Company will be eligible for an additional 180-day compliance period if it meets the Nasdaq SmallCap Market initial listing criteria as set forth in Nasdaq Marketplace Rule 4310(c) other than the minimum bid price requirement. If the Company is not eligible for an additional compliance period, or does not regain compliance during any additional compliance period, Nasdaq will provide written notice to the Company that its securities will be delisted. At such time, the Company would be able to appeal the delisting determination to a Nasdaq Listing Qualifications Panel.

About Axonyx

Axonyx Inc. is a U.S.-based biopharmaceutical company engaged in the acquisition and development of proprietary pharmaceutical compounds for the treatment of Central Nervous System disorders. The Company currently has three compounds in development for Alzheimer's disease, namely Phenserine - a potential symptomatic and disease progression treatment of mild to moderate Alzheimer's Disease (AD), Posiphen(TM) - a potential disease progression treatment for AD now in Phase I, and BisNorCymcerine (BNC) - a potential symptomatic treatment of severe AD now in pre-Investigational New Drug (IND) stage.

This press release may contain forward-looking statements or predictions. These statements represent our judgment to date, and are subject to risks and uncertainties that could materially affect the Company, including those risks and uncertainties described in the documents Axonyx files from time to time with the SEC, specifically Axonyx's annual report on Form 10-K. Specifically, with respect to our drug candidates Phenserine, Posiphen(TM) and BisNorCymcerine, Axonyx cannot assure that: any preclinical studies or clinical trials, whether ongoing or conducted in the future, will prove successful, and if successful, that the results can be replicated; safety and efficacy profiles of any of its drug candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; pre-clinical results related to cognition and the regulation of beta-APP will be substantiated by ongoing or future clinical trials, if any, or that any of its drug candidates will be able to improve the signs or symptoms of their respective clinical indication or slow the progression of Alzheimer's disease; any of its drug candidates will support an NDA filing or its equivalent, will be approved by the FDA or its equivalent, or if approved, will prove competitive in the market; or that Axonyx will have or obtain the necessary financing to support its drug development programs. Axonyx cannot assure that it will be successful with regard to identifying a (sub-) licensing partner for any of its compounds. Axonyx undertakes no obligation to publicly release the result of any revisions to such forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Dec 22, 2005
Words:644
Previous Article:Brightpoint Announces Sale of France Operations.
Next Article:Best Buy Acquires Pacific Sales Kitchen and Bath Centers, Inc.; California Retailer Caters to Upscale Remodelers; Extends Best Buy's Reach With...
Topics:



Related Articles
SAVVIS Receives Nasdaq Notice of 180-Day Grace Period, Extendable to 360 Days, to Regain Compliance with Minimum Bid Price Rule.
StockerYale, Inc. Announces Accelerated Vesting of Stock Options; Company Receives Nasdaq Deficiency Notice Related to Minimum Bid Price Rule.
Xcyte Receives Notice of Non-Compliance with Nasdaq Continued Listing Standard.
PRG-Schultz Receives Nasdaq Deficiency Notice Related to Minimum Bid Price Rule.
Saflink Receives NASDAQ Deficiency Notice Related to Minimum Bid Price; No Effect on Listing While Company Has a Minimum of 180 Days to Cure...
Axonyx Regains Compliance with Nasdaq Minimum Bid Price Rule.
Axonyx Receives Notice Related to Nasdaq Minimum Bid Price Rule.
Verso Receives Notice from Nasdaq; Share Price Below $1 Minimum Bid Price Requirement.
JMAR Receives Hearing Date for Nasdaq Appeal.
Transmeta Receives Letter from Nasdaq Regarding Noncompliance with Minimum Bid Price Rule.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters